Feng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feng Wang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Yalan Yang
The First Affiliated Hospital of Zhengzhou University
3 shared publicationsYikai Han
Department of Oncology, The First Affiliated Hospital of Zhengzhou University
3 shared publicationsYuanyuan Yang
The First Affiliated Hospital of Zhengzhou University
3 shared publicationsDao Xin
Department of Oncology, The First Affiliated Hospital of Zhengzhou University
2 shared publicationsJiaxin Pei
The First Affiliated Hospital of Zhengzhou University
2 shared publicationsLulu Guan
The First Affiliated Hospital of Zhengzhou University
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1953814
All-trans retinoic acid in solid-tumour immunity: context-dependent signalling, cellular states, and combination therapy
All-trans retinoic acid (ATRA) influences several processes relevant to cancer immunotherapy, yet its effects in solid tumours range from relief of myeloid suppression to reinforcement of immune tolerance. This divergence reflects the source and duration of retinoid exposure, the molecular state of responding cells and the phase of treatment. We examine these determinants across myeloid, tumour-cell, lymphoid and stromal compartments, distinguishing administered ATRA and ATRA-containing formulations from locally produced retinoic acid (RA) and interventions targeting the RA pathway. Local synthesis and CYP26-mediated catabolism regulate availability, whereas intracellular binding proteins, RAR/RXR complexes, transcriptional coregulators and chromatin influence the response to that exposure. Interactions with interferon, TGF-β, IL-10 and PD-L1 further connect retinoid signalling to immune recognition, regulation and adaptive resistance. Experimental studies support distinct combination strategies based on myeloid differentiation, tumour-cell recognition, preservation of effector function and stromal reprogramming. Human immunotherapy studies show pharmacodynamic activity and combination feasibility, with mixed clinical results across uncontrolled and comparative cohorts. We propose that translation should prioritise a defined, reversible barrier to immunity, pair blood measurements with functional tumour sampling, and compare ATRA-containing treatment with the same partner regimen alone. This approach gives context dependence a testable basis and directs ATRA development towards biologically selected combinations.
- 20 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1953814
Open AccessAll-trans retinoic acid in solid-tumour immunity: context-dependent signalling, cellular states, and combination therapy
All-trans retinoic acid (ATRA) influences several processes relevant to cancer immunotherapy, yet its effects in solid tumours range from relief of myeloid suppression to reinforcement of immune tolerance. This divergence reflects the source and duration of retinoid exposure, the molecular state of responding cells and the phase of treatment. We examine these determinants across myeloid, tumour-cell, lymphoid and stromal compartments, distinguishing administered ATRA and ATRA-containing formulations from locally produced retinoic acid (RA) and interventions targeting the RA pathway. Local synthesis and CYP26-mediated catabolism regulate availability, whereas intracellular binding proteins, RAR/RXR complexes, transcriptional coregulators and chromatin influence the response to that exposure. Interactions with interferon, TGF-β, IL-10 and PD-L1 further connect retinoid signalling to immune recognition, regulation and adaptive resistance. Experimental studies support distinct combination strategies based on myeloid differentiation, tumour-cell recognition, preservation of effector function and stromal reprogramming. Human immunotherapy studies show pharmacodynamic activity and combination feasibility, with mixed clinical results across uncontrolled and comparative cohorts. We propose that translation should prioritise a defined, reversible barrier to immunity, pair blood measurements with functional tumour sampling, and compare ATRA-containing treatment with the same partner regimen alone. This approach gives context dependence a testable basis and directs ATRA development towards biologically selected combinations.
- Open Access
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1833717
Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer
Background: Trousseau syndrome-related cerebral infarction (TSCI) is a severe complication of lung cancer, but tools for early risk stratification remain limited. Methods: In this retrospective case-control study, we enrolled 94 patients with newly diagnosed lung cancer and TSCI and 94 matched lung cancer controls without stroke at the First Affiliated Hospital of Zhengzhou University between 2021 and 2025. Using cases in which TSCI occurred at diagnosis or within 6 months thereafter, we developed and internally validated a five-variable model based on serum magnesium, international normalized ratio, prothrombin time, albumin-to-globulin ratio, and a history of hypertension. Concurrent-onset (Fulminant) and delayed-onset TSCI subgroups were compared across coagulation, inflammatory, tumor-burden, and nutritional domains. Temporal biomarker patterns were examined using locally estimated scatterplot smoothing (LOESS). Results: The model showed good discrimination (AUC = 0.861) and sample-specific calibration within the selected case-control sample. Fulminant TSCI showed pronounced abnormalities across coagulation/fibrinolysis, inflammatory, tumor-burden, and nutritional domains. Temporal analyses suggested heterogeneity in biomarker patterns: early-onset TSCI was associated with higher Ki67, neuron-specific enolase, and lactate dehydrogenase, whereas late-onset TSCI was more closely associated with higher triglyceride levels. Conclusions: These findings identify a set of routinely available clinical variables associated with early high-risk TSCI in patients with lung cancer. The proposed nomogram demonstrated favorable discriminative performance and may provide a useful framework for early risk stratification and clinical surveillance. Further validation in independent prospective cohorts would help to confirm its generalizability and support future clinical application.
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1833717
Open AccessEarly risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer
Background: Trousseau syndrome-related cerebral infarction (TSCI) is a severe complication of lung cancer, but tools for early risk stratification remain limited. Methods: In this retrospective case-control study, we enrolled 94 patients with newly diagnosed lung cancer and TSCI and 94 matched lung cancer controls without stroke at the First Affiliated Hospital of Zhengzhou University between 2021 and 2025. Using cases in which TSCI occurred at diagnosis or within 6 months thereafter, we developed and internally validated a five-variable model based on serum magnesium, international normalized ratio, prothrombin time, albumin-to-globulin ratio, and a history of hypertension. Concurrent-onset (Fulminant) and delayed-onset TSCI subgroups were compared across coagulation, inflammatory, tumor-burden, and nutritional domains. Temporal biomarker patterns were examined using locally estimated scatterplot smoothing (LOESS). Results: The model showed good discrimination (AUC = 0.861) and sample-specific calibration within the selected case-control sample. Fulminant TSCI showed pronounced abnormalities across coagulation/fibrinolysis, inflammatory, tumor-burden, and nutritional domains. Temporal analyses suggested heterogeneity in biomarker patterns: early-onset TSCI was associated with higher Ki67, neuron-specific enolase, and lactate dehydrogenase, whereas late-onset TSCI was more closely associated with higher triglyceride levels. Conclusions: These findings identify a set of routinely available clinical variables associated with early high-risk TSCI in patients with lung cancer. The proposed nomogram demonstrated favorable discriminative performance and may provide a useful framework for early risk stratification and clinical surveillance. Further validation in independent prospective cohorts would help to confirm its generalizability and support future clinical application.
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1704359
Tracking temporal shifts of peripheral blood NLR, PLR, and ALB: a prognostic tool for PD-1 inhibitor efficacy in advanced malignant melanoma
Objective: PD-1 monoclonal antibodies are cornerstone therapies for advanced malignant melanoma, yet treatment response varies greatly between patients. This study investigated temporal changes in peripheral blood inflammatory and nutritional parameters during PD-1 therapy, examined their associations with clinical outcomes, and identified prognostic biomarkers. Methods: A retrospective analysis was conducted on 99 patients with advanced malignant melanoma who received PD-1 monoclonal antibody treatment at the First Affiliated Hospital of Zhengzhou University (January 2019–September 2024). Imaging evaluations (CT/MRI, with PET-CT for suspected distant metastasis) were performed at baseline (T0, before treatment), the end of the 2nd cycle (T2), and the end of the 4th cycle (T4) to assess treatment response per the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).After four treatment cycles, patients were stratified into a clinical benefit group (complete response [CR] + partial response [PR] + stable disease [SD], n=68) and a non-benefit group (progressive disease [PD], n=31) based on the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST). Peripheral blood samples were collected at five time points: baseline (T0), post-first cycle (T1), post-second cycle (T2), post-third cycle (T3), and post-fourth cycle (T4). Dynamic changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), serum albumin (ALB), and prognostic nutritional index (PNI) were compared between groups. Line graphs and box plots were used to visualize indicator trends, while logistic regression and receiver operating characteristic (ROC) curves were applied to evaluate prognostic value. Results: Non-benefit patients showed NLR peaks at T2 and PLR peaks at T1, while benefit patients had stable levels. ALB and PNI were higher and stable in the benefit group (P<0.05). A model combining T1PLR, T1ALB, and T2NLR achieved an AUC of 0.89 (sensitivity 0.90, specificity 0.79). Conclusion: Dynamic monitoring of peripheral blood NLR, PLR, and ALB provides critical insights for predicting PD-1 immunotherapy efficacy in patients with advanced malignant melanoma. These indicators hold promise as potential clinical biomarkers to guide the development of individualized treatment strategies.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1704359
Open AccessTracking temporal shifts of peripheral blood NLR, PLR, and ALB: a prognostic tool for PD-1 inhibitor efficacy in advanced malignant melanoma
Objective: PD-1 monoclonal antibodies are cornerstone therapies for advanced malignant melanoma, yet treatment response varies greatly between patients. This study investigated temporal changes in peripheral blood inflammatory and nutritional parameters during PD-1 therapy, examined their associations with clinical outcomes, and identified prognostic biomarkers. Methods: A retrospective analysis was conducted on 99 patients with advanced malignant melanoma who received PD-1 monoclonal antibody treatment at the First Affiliated Hospital of Zhengzhou University (January 2019–September 2024). Imaging evaluations (CT/MRI, with PET-CT for suspected distant metastasis) were performed at baseline (T0, before treatment), the end of the 2nd cycle (T2), and the end of the 4th cycle (T4) to assess treatment response per the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).After four treatment cycles, patients were stratified into a clinical benefit group (complete response [CR] + partial response [PR] + stable disease [SD], n=68) and a non-benefit group (progressive disease [PD], n=31) based on the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST). Peripheral blood samples were collected at five time points: baseline (T0), post-first cycle (T1), post-second cycle (T2), post-third cycle (T3), and post-fourth cycle (T4). Dynamic changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), serum albumin (ALB), and prognostic nutritional index (PNI) were compared between groups. Line graphs and box plots were used to visualize indicator trends, while logistic regression and receiver operating characteristic (ROC) curves were applied to evaluate prognostic value. Results: Non-benefit patients showed NLR peaks at T2 and PLR peaks at T1, while benefit patients had stable levels. ALB and PNI were higher and stable in the benefit group (P<0.05). A model combining T1PLR, T1ALB, and T2NLR achieved an AUC of 0.89 (sensitivity 0.90, specificity 0.79). Conclusion: Dynamic monitoring of peripheral blood NLR, PLR, and ALB provides critical insights for predicting PD-1 immunotherapy efficacy in patients with advanced malignant melanoma. These indicators hold promise as potential clinical biomarkers to guide the development of individualized treatment strategies.
- Open Access
- 18 July 2023
- Published by Springer Nature in Research Square
Causal associations between total testosterone level and non-small cell lung cancer: a two-sample Mendelian randomization study
Purpose: The study aimed to evaluate the causal association between the level of total testosterone and the risk of non-small cell lung cancer (NSCLC) utilizing Mendelian randomization (MR) approach. Methods: Genetic variants extracted from genome-wide association studies (GWAS) datasets of total testosterone level and NSCLC were utilized as instrumental variables (IVs). Five methods were employed to generate overall estimates of the effect, including the inverse variance weighted (IVW), MR Egger, maximum likelihood (ML), weighted median, and IVW (multiplicative random effects). Leave-one-out validation, MR Steiger test, pleiotropy and heterogeneity testing were conducted to ensure the reliability of our results. Results: The MR analysis demonstrated a causal effect between total testosterone level and NSCLC, IVW (OR = 0.74, 95% CI = 0.60-0.92, P= 7.44E-03), MR Egger (OR = 0.53, 95% CI = 0.34-0.84, P = 6.98E-03), ML (OR = 0.74, 95% CI = 0.61-0.91, P = 3.49E-03), weighted median (OR = 0.66, 95% CI = 0.48-0.91, P = 1.25E-03), and IVW (multiplicative random effects) (OR = 0.74, 95% CI = 0.60-0.92, P = 7.44E-03). The leave-one-out test revealed that removing any IV did not significantly alter the results. The MR Steiger test confirmed the direction of causality. The absence of significant pleiotropy and negligible effect of heterogeneity supported our finding. Conclusion: According to our findings, increased levels of testosterone may potentially reduce the likelihood of developing NSCLC. These outcomes could provide valuable insights for the advancement of innovative therapeutic strategies manipulating testosterone levels to lower the risk of NSCLC.
- 18 July 2023
- Published by Springer Nature in Research Square
Open AccessCausal associations between total testosterone level and non-small cell lung cancer: a two-sample Mendelian randomization study
Purpose: The study aimed to evaluate the causal association between the level of total testosterone and the risk of non-small cell lung cancer (NSCLC) utilizing Mendelian randomization (MR) approach. Methods: Genetic variants extracted from genome-wide association studies (GWAS) datasets of total testosterone level and NSCLC were utilized as instrumental variables (IVs). Five methods were employed to generate overall estimates of the effect, including the inverse variance weighted (IVW), MR Egger, maximum likelihood (ML), weighted median, and IVW (multiplicative random effects). Leave-one-out validation, MR Steiger test, pleiotropy and heterogeneity testing were conducted to ensure the reliability of our results. Results: The MR analysis demonstrated a causal effect between total testosterone level and NSCLC, IVW (OR = 0.74, 95% CI = 0.60-0.92, P= 7.44E-03), MR Egger (OR = 0.53, 95% CI = 0.34-0.84, P = 6.98E-03), ML (OR = 0.74, 95% CI = 0.61-0.91, P = 3.49E-03), weighted median (OR = 0.66, 95% CI = 0.48-0.91, P = 1.25E-03), and IVW (multiplicative random effects) (OR = 0.74, 95% CI = 0.60-0.92, P = 7.44E-03). The leave-one-out test revealed that removing any IV did not significantly alter the results. The MR Steiger test confirmed the direction of causality. The absence of significant pleiotropy and negligible effect of heterogeneity supported our finding. Conclusion: According to our findings, increased levels of testosterone may potentially reduce the likelihood of developing NSCLC. These outcomes could provide valuable insights for the advancement of innovative therapeutic strategies manipulating testosterone levels to lower the risk of NSCLC.
- Open Access
- 17 November 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 983892
Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
Objectives: The study aims to summarize publication characteristics of anti-programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immunotherapy for esophageal cancer and create scientific maps to explore hotspots and emerging trends with bibliometric methods.Methods: The publications between 2012 and 2021 were retrieved from the Web of Science Core Collection (WoSCC) on June 20, 2022. Bibliometric tools including HistCite, VOSviewer, and CiteSpace were used for statistical analysis. Data on the trend of the annual output, countries/regions, institutions, journals, authors, subject categories, keywords, and co-cited references were presented in this study.Results: A total of 552 publications written by 3,623 authors of 872 institutions, 44 countries/regions in 250 journals were included in the bibliometric study. China, USA and Japan were the key countries in this field. Kato Ken, Bang Yung-Jue, Frontiers in Oncology, Journal of Clinical Oncology and Natl Canc Ctr were the top 1 productive author, co-cited author, productive journal, co-cited journal and prolific institution, respectively. The top 4 most present keywords were esophageal cancer, immunotherapy, esophageal squamous cell carcinoma and PD-L1. Neoadjuvant chemotherapy, response, PD-1 blockade and CD8+ T cell were four latest research frontiers. The keywords reflected the progress from PD-1/PD-L1 expression to the clinical application of PD-1/PD-L1 inhibitors. The current researches mainly focus on neoadjuvant immunotherapy for esophageal cancer and development of biomarkers. Further research is warranted to determine effective predictive biomarkers or models, illustrate the molecular mechanism of combined treatment, and construct the optimal therapeutic strategy.Conclusions: This study visually analyzed the global trend and hotspots of anti-PD-1/PD-L1 immunotherapy for esophageal cancer over the past decade. The results could guide scientists to comprehensively understand the global frontiers and determine future directions.
- 17 November 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 983892
Open AccessResearch trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
Objectives: The study aims to summarize publication characteristics of anti-programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immunotherapy for esophageal cancer and create scientific maps to explore hotspots and emerging trends with bibliometric methods.Methods: The publications between 2012 and 2021 were retrieved from the Web of Science Core Collection (WoSCC) on June 20, 2022. Bibliometric tools including HistCite, VOSviewer, and CiteSpace were used for statistical analysis. Data on the trend of the annual output, countries/regions, institutions, journals, authors, subject categories, keywords, and co-cited references were presented in this study.Results: A total of 552 publications written by 3,623 authors of 872 institutions, 44 countries/regions in 250 journals were included in the bibliometric study. China, USA and Japan were the key countries in this field. Kato Ken, Bang Yung-Jue, Frontiers in Oncology, Journal of Clinical Oncology and Natl Canc Ctr were the top 1 productive author, co-cited author, productive journal, co-cited journal and prolific institution, respectively. The top 4 most present keywords were esophageal cancer, immunotherapy, esophageal squamous cell carcinoma and PD-L1. Neoadjuvant chemotherapy, response, PD-1 blockade and CD8+ T cell were four latest research frontiers. The keywords reflected the progress from PD-1/PD-L1 expression to the clinical application of PD-1/PD-L1 inhibitors. The current researches mainly focus on neoadjuvant immunotherapy for esophageal cancer and development of biomarkers. Further research is warranted to determine effective predictive biomarkers or models, illustrate the molecular mechanism of combined treatment, and construct the optimal therapeutic strategy.Conclusions: This study visually analyzed the global trend and hotspots of anti-PD-1/PD-L1 immunotherapy for esophageal cancer over the past decade. The results could guide scientists to comprehensively understand the global frontiers and determine future directions.
- Open Access
- 29 April 2022
- Published by Springer Nature in Research Square
The value of preoperative nutritional status, the systemic inflammation index and a nomogram for the prognosis of patients with esophageal cancer after radical resection
Background Controlling nutritional status (CONUT), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) are new parameters that reflect the immune-nutritional status in some cancers. Purpose To investigate the relationship between preoperative nutritional status and systemic inflammatory indexes on the clinicopathological prognosis of patients with stage I-IV esophageal cancer and to clarify the predictive value of nutritional status and inflammatory indexes on tumor recurrence, metastasis and long-term survival after radical resection. Methods The clinical data of 381 patients who underwent radical esophagectomy at the First Affiliated Hospital of Zhengzhou University from August 5, 2013, to August 1, 2021, were analyzed retrospectively. The preoperative clinical characteristics and hematological examination results were collected, the data on nutritional and immune status were analyzed, tumor recurrence and survival were evaluated by telephone follow-up, and overall survival (OS) and progression-free survival (PFS) were calculated. Nutritional data and the immune status, clinical data and survival information were also analyzed. Results Analysis of the clinical data of 381 patients with esophageal cancer undergoing radical esophagectomy revealed that preoperative nutritional status was related to preoperative complications, neoadjuvant therapy, TNM stage, tumor location, pathological type, vascular invasion, nerve invasion and regional lymph node metastasis, and the indexes of systemic inflammation were related to neoadjuvant therapy, TNM stage, tumor location, pathological type and nerve invasion. In univariate analysis, vascular invasion, preoperative CONUT, PNI and SII were identified as important factors affecting prognosis. In multivariate analysis, vascular invasion, preoperative CONUT, PNI, and SII were identified as important factors showing an independent correlation with survival time. A nomogram was developed, and the statistically significant influencing factors from the multivariate Cox regression model were included to predict the 2-, 3- and 5-year overall survival rates of patients with lung metastasis from gastric cancer. Conclusion CONUT, PNI and SII are independent risk factors for predicting overall survival and recurrence-free survival after radical resection of esophageal cancer. The proposed nomogram prediction model can aid in individualized analysis of the prognosis of these patients.
- 29 April 2022
- Published by Springer Nature in Research Square
Open AccessThe value of preoperative nutritional status, the systemic inflammation index and a nomogram for the prognosis of patients with esophageal cancer after radical resection
Background Controlling nutritional status (CONUT), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) are new parameters that reflect the immune-nutritional status in some cancers. Purpose To investigate the relationship between preoperative nutritional status and systemic inflammatory indexes on the clinicopathological prognosis of patients with stage I-IV esophageal cancer and to clarify the predictive value of nutritional status and inflammatory indexes on tumor recurrence, metastasis and long-term survival after radical resection. Methods The clinical data of 381 patients who underwent radical esophagectomy at the First Affiliated Hospital of Zhengzhou University from August 5, 2013, to August 1, 2021, were analyzed retrospectively. The preoperative clinical characteristics and hematological examination results were collected, the data on nutritional and immune status were analyzed, tumor recurrence and survival were evaluated by telephone follow-up, and overall survival (OS) and progression-free survival (PFS) were calculated. Nutritional data and the immune status, clinical data and survival information were also analyzed. Results Analysis of the clinical data of 381 patients with esophageal cancer undergoing radical esophagectomy revealed that preoperative nutritional status was related to preoperative complications, neoadjuvant therapy, TNM stage, tumor location, pathological type, vascular invasion, nerve invasion and regional lymph node metastasis, and the indexes of systemic inflammation were related to neoadjuvant therapy, TNM stage, tumor location, pathological type and nerve invasion. In univariate analysis, vascular invasion, preoperative CONUT, PNI and SII were identified as important factors affecting prognosis. In multivariate analysis, vascular invasion, preoperative CONUT, PNI, and SII were identified as important factors showing an independent correlation with survival time. A nomogram was developed, and the statistically significant influencing factors from the multivariate Cox regression model were included to predict the 2-, 3- and 5-year overall survival rates of patients with lung metastasis from gastric cancer. Conclusion CONUT, PNI and SII are independent risk factors for predicting overall survival and recurrence-free survival after radical resection of esophageal cancer. The proposed nomogram prediction model can aid in individualized analysis of the prognosis of these patients.
- Open Access
- 1 January 2022
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12  (6) , 2860-2893
Recent progress of carbon dots in targeted bioimaging and cancer therapy
Carbon dots (CDs), as one new class of carbon nanomaterials with various structure and extraordinary physicochemical properties, have attracted tremendous interest for their potential applications in tumor theranostics, especially in targeted bioimaging and therapy. In these areas, CDs and its derivatives have been employed as highly efficient imaging agent for photoluminescence bioimaging of tumors cells. With unique structure, optical and/or dose attention properties, CDs have been harnessed in various nanotheranostic strategies for diverse tumors through integrating with other functional nanoparticles or utilizing their inherent physical properties. Up to now, CDs have been approved as novel biomaterials by their excellent performances in precise targeted bioimaging and therapy for tumors. Herein, the latest progress in the development of CDs in targeted bioimaging and tumor therapy are reviewed. Meanwhile, the challenges and future prospects of the application of CDs in promising nanotheranostic strategies are discussed and proposed.
- 1 January 2022
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12  (6) , 2860-2893
Open AccessRecent progress of carbon dots in targeted bioimaging and cancer therapy
Carbon dots (CDs), as one new class of carbon nanomaterials with various structure and extraordinary physicochemical properties, have attracted tremendous interest for their potential applications in tumor theranostics, especially in targeted bioimaging and therapy. In these areas, CDs and its derivatives have been employed as highly efficient imaging agent for photoluminescence bioimaging of tumors cells. With unique structure, optical and/or dose attention properties, CDs have been harnessed in various nanotheranostic strategies for diverse tumors through integrating with other functional nanoparticles or utilizing their inherent physical properties. Up to now, CDs have been approved as novel biomaterials by their excellent performances in precise targeted bioimaging and therapy for tumors. Herein, the latest progress in the development of CDs in targeted bioimaging and tumor therapy are reviewed. Meanwhile, the challenges and future prospects of the application of CDs in promising nanotheranostic strategies are discussed and proposed.
- Open Access
- 22 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway
Purpose: To characterize the mechanism by which metformin inhibits PD-L1 expression in esophageal squamous cell carcinoma (ESCC) and to evaluate the effect of metformin on the antitumor immune response.Methods: The Cancer Genome Atlas (TCGA) database was used to analyze the correlations between IL-6 and prognosis and between IL-6 and PD-L1 gene expression in esophageal cancer. Reverse transcription-quantitative polymerase chain reaction (RT-PCR), Western blotting and immunofluorescence were used to study the mechanism by which metformin affects PD-L1 expression. Additionally, T cell function was assessed in a coculture system containing ESCC cells and peripheral blood mononuclear cells (PBMCs) treated with metformin or IL-6. In an in vivo assay, we used a model established with NPIdKOâ„¢ mice, which have a reconstituted immune system generated by transplanting PBMCs through intravenous injection, to evaluate the effect of metformin on tumors.Results: The TCGA esophageal cancer data showed that IL-6 expression was positively correlated with PD-L1 expression and that patients with high IL-6 expression had a significantly lower overall survival rate than patients with low IL-6 expression. PD-L1 expression in ESCC cell lines was significantly inhibited by metformin via the IL-6/JAK2/STAT3 signaling pathway but was not correlated with the canonical AMPK pathway. In the coculture system, the metformin pretreatment group showed higher T cell activation and better T cell killing function than the control group. Animal experiments confirmed that metformin downregulated PD-L1 expression and that combination treatment with metformin and PD-1 inhibitors synergistically enhanced the antitumor response.Conclusions: Metformin downregulated PD-L1 expression by blocking the IL-6/JAK2/STAT3 signaling pathway in ESCC, which enhanced the antitumor immune response.
- 22 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessMetformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway
Purpose: To characterize the mechanism by which metformin inhibits PD-L1 expression in esophageal squamous cell carcinoma (ESCC) and to evaluate the effect of metformin on the antitumor immune response.Methods: The Cancer Genome Atlas (TCGA) database was used to analyze the correlations between IL-6 and prognosis and between IL-6 and PD-L1 gene expression in esophageal cancer. Reverse transcription-quantitative polymerase chain reaction (RT-PCR), Western blotting and immunofluorescence were used to study the mechanism by which metformin affects PD-L1 expression. Additionally, T cell function was assessed in a coculture system containing ESCC cells and peripheral blood mononuclear cells (PBMCs) treated with metformin or IL-6. In an in vivo assay, we used a model established with NPIdKOâ„¢ mice, which have a reconstituted immune system generated by transplanting PBMCs through intravenous injection, to evaluate the effect of metformin on tumors.Results: The TCGA esophageal cancer data showed that IL-6 expression was positively correlated with PD-L1 expression and that patients with high IL-6 expression had a significantly lower overall survival rate than patients with low IL-6 expression. PD-L1 expression in ESCC cell lines was significantly inhibited by metformin via the IL-6/JAK2/STAT3 signaling pathway but was not correlated with the canonical AMPK pathway. In the coculture system, the metformin pretreatment group showed higher T cell activation and better T cell killing function than the control group. Animal experiments confirmed that metformin downregulated PD-L1 expression and that combination treatment with metformin and PD-1 inhibitors synergistically enhanced the antitumor response.Conclusions: Metformin downregulated PD-L1 expression by blocking the IL-6/JAK2/STAT3 signaling pathway in ESCC, which enhanced the antitumor immune response.
- Open Access
- 1 September 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 7791-7799
Predictive Significance Of Preoperative Systemic Immune-Inflammation Index Determination In Postoperative Liver Metastasis Of Colorectal Cancer
Purpose: Systemic inflammation and immune dysfunction have been proved to be significantly associated with cancer progression and metastasis in colorectal cancer (CRC). The aim of this retrospective study was to investigate the association between preoperative systemic immune-inflammation index (SII) and postoperative liver metastasis in CRC. Patients and methods: This retrospective study evaluated 182 patients with CRC who underwent surgical resection. The inflammation-based prognostic factors, including SII, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and prognostic nutritional index (PNI), were calculated based on preoperative laboratory data. The univariate and multivariate logistic regression analysis was performed to identify the risk factors correlated with postoperative liver metastasis in CRC. Receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were respectively used to assess the predictive ability and clinical usefulness of SII for postoperative liver metastasis in CRC. Results: The univariate and multivariable analysis confirmed SII was independently correlated with postoperative liver metastasis in CRC (pConclusion: SII is an independent predictive indicator of postoperative liver metastasis for patients with colorectal cancer.
- 1 September 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 7791-7799
Open AccessPredictive Significance Of Preoperative Systemic Immune-Inflammation Index Determination In Postoperative Liver Metastasis Of Colorectal Cancer
Purpose: Systemic inflammation and immune dysfunction have been proved to be significantly associated with cancer progression and metastasis in colorectal cancer (CRC). The aim of this retrospective study was to investigate the association between preoperative systemic immune-inflammation index (SII) and postoperative liver metastasis in CRC. Patients and methods: This retrospective study evaluated 182 patients with CRC who underwent surgical resection. The inflammation-based prognostic factors, including SII, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and prognostic nutritional index (PNI), were calculated based on preoperative laboratory data. The univariate and multivariate logistic regression analysis was performed to identify the risk factors correlated with postoperative liver metastasis in CRC. Receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were respectively used to assess the predictive ability and clinical usefulness of SII for postoperative liver metastasis in CRC. Results: The univariate and multivariable analysis confirmed SII was independently correlated with postoperative liver metastasis in CRC (pConclusion: SII is an independent predictive indicator of postoperative liver metastasis for patients with colorectal cancer.
- 30 November 2018
- Vol. 38  (11) , 1325-1330
[SIRT1 participates in epithelial-mesenchymal transition of EC-9706 and Eca-109 cells in vitro by regulating Snail expression].
To explore the role of SIRT1 in the occurrence of epithelial-mesenchymal transition (EMT) in EC-9706 and Eca-109 cells and the possible mechanism. Three chemically synthesized siRNA targeting SIRT1 were transfected into EC-9706 and Eca-109 cells with the non-transfected cells and cells transfected with the negative siRNAs as controls. Real-time PCR and Western blotting were used to detect the expressions of SIRT1, E-cadherin, vimentin, Snail, Twist1 and ZEB in the cells. Transwell invasion assay and wounding healing assay were used to examine the changes in the invasion and metastasis abilities of the cells after transfection. EC-9706 and Eca-109 cells transfected with SIRT1 siRNA1 and SIRT1 siRNA3 showed significantly decreased mRNA and protein expressions of SIRT1 (P < 0.05). Transwell invasion assay and wounding healing assay showed that transfection with SIRT1 siRNA1 and SIRT1 siRNA3 caused significantly lowered invasion and metastasis abilities in EC-9706 and Eca-109 cells (P < 0.05). In EC-9706 and Eca-109 cells transfected with SIRT1 siRNA1 and SIRT1 siRNA3, the expression level of E-cadherin was significantly increased while the expressions of vimentin, Snail and Twist were significantly lowered (P < 0.05). SIRT1 participates in the invasion and metastasis of EC-9706 and Eca- 109 cells probably by inducing EMT via regulating the expression of Snail.
- 30 November 2018
- Vol. 38  (11) , 1325-1330
[SIRT1 participates in epithelial-mesenchymal transition of EC-9706 and Eca-109 cells in vitro by regulating Snail expression].
To explore the role of SIRT1 in the occurrence of epithelial-mesenchymal transition (EMT) in EC-9706 and Eca-109 cells and the possible mechanism. Three chemically synthesized siRNA targeting SIRT1 were transfected into EC-9706 and Eca-109 cells with the non-transfected cells and cells transfected with the negative siRNAs as controls. Real-time PCR and Western blotting were used to detect the expressions of SIRT1, E-cadherin, vimentin, Snail, Twist1 and ZEB in the cells. Transwell invasion assay and wounding healing assay were used to examine the changes in the invasion and metastasis abilities of the cells after transfection. EC-9706 and Eca-109 cells transfected with SIRT1 siRNA1 and SIRT1 siRNA3 showed significantly decreased mRNA and protein expressions of SIRT1 (P < 0.05). Transwell invasion assay and wounding healing assay showed that transfection with SIRT1 siRNA1 and SIRT1 siRNA3 caused significantly lowered invasion and metastasis abilities in EC-9706 and Eca-109 cells (P < 0.05). In EC-9706 and Eca-109 cells transfected with SIRT1 siRNA1 and SIRT1 siRNA3, the expression level of E-cadherin was significantly increased while the expressions of vimentin, Snail and Twist were significantly lowered (P < 0.05). SIRT1 participates in the invasion and metastasis of EC-9706 and Eca- 109 cells probably by inducing EMT via regulating the expression of Snail.